Clinical development program in pediatric osteosarcoma will leverage orphan drug status. May 27, 2014 Advaxis, Inc., a leader in developing cancer immunotherapies, announced that …
Advaxis to Initiate Clinical Development of ADXS-cHER2 Immunotherapy to Treat Pediatric Bone Cancer
Clinical data in canine osteosarcoma presented at sarcoma foundation of America annual Conference. May 5, 2014 Advaxis, Inc., a biotechnology company developing cancer immunotherapies, announced it …